NCI-2024-00437

A MULTICENTER, OPEN-LABEL PHASE 1/1B DOSE-FINDING, SAFETY, AND PHARMACOKINETIC STUDY OF MBRC-101, AN ANTI-EPHA5 MONOMETHYL AURISTATIN E(MMAE) ANTIBODY DRUG CONJUGATE, IN ADVANCED REFRACTORY SOLID TUMORS

This is a Phase 1/1b researh study testing a new drug called MBRC-101 in people with advanced solid tumors that have stopped responding to other treatments. MBRC-101 is an antibody-drug conjugate (ADC) that targets a protein called EphA5 found on the surface of certain solid tumors, including some types of lung, breast, prostate, and brain cancers. It is not typically found in high levels on healthy cells, making it a good target for therapies like MBRC-101. The drug works by delivering a cancer-killing agent (MMAE) directly to those cells, helping to reduce damage to healthy tissue. MBRC-101 could be a promising new targeted treatment for patients with cancers that express EphA5, especially those who have exhausted standard options. If it proves to be safe and shows early signs of benefit, it will move into larger trials to better assess how well it works.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

Antibody-drug conjugate: ADCs have two parts: an antibody that targets cancer cells and a chemotherapy drug that kills cancer cells.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06014658

Clinical Trial Site: Columbia

To see all available clinical trials click here.